The adverse reactions observed were consistent with those observed in clinical trials of VEKLURY in adults.
The following adverse reactions have been identified during use of VEKLURY under Emergency Use Authorization:
- General disorders and administration site conditions: Administration site extravasation
- Skin and subcutaneous tissue disorders: Rash
- Immune system disorders: Anaphylaxis, angioedema, infusion-related reactions, hypersensitivity
- Investigations: Transaminase elevations
Risk Summary
Available data from a clinical trial (IMPAACT 2032), published reports, the COVID-PR pregnancy exposure registry, and compassionate use of remdesivir in pregnant individuals have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes following exposure in the second and third trimester. However, there are insufficient pregnancy data available to evaluate the risk of remdesivir exposure during the first trimester. A study evaluating the pharmacokinetics of remdesivir during pregnancy demonstrated no clinically relevant differences between pregnant and non-pregnant individuals. No dose adjustments are recommended in patients who receive VEKLURY during pregnancy (see Data) and [see Clinical Pharmacology (12.3)]. In nonclinical reproductive toxicity studies, remdesivir demonstrated no adverse effect on embryo-fetal development when administered to pregnant animals at systemic exposures (AUC) of the predominant circulating metabolite of remdesivir (GS-441524) that were 4 times (rats and rabbits) the exposure in humans at the recommended human dose (RHD) (see Data). There are maternal and fetal risks associated with untreated COVID-19 in pregnancy (see Clinical Considerations).
The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
Clinical Considerations
Disease-associated maternal and/or embryo-fetal risk
COVID-19 in pregnancy is associated with adverse maternal and fetal outcomes, including preeclampsia, eclampsia, preterm birth, premature rupture of membranes, venous thromboembolic disease, and fetal death.
Data
Human Data
A non-randomized, open-label clinical study (IMPAACT 2032) evaluated pharmacokinetics and safety of up to 10 days of treatment with VEKLURY in 25 hospitalized pregnant and 28 hospitalized non-pregnant individuals of childbearing potential. Subjects received VEKLURY 200 mg once daily for 1 day followed by VEKLURY 100 mg once daily on subsequent days via intravenous infusion. Subjects were enrolled prior to their fourth VEKLURY infusion. Assessments occurred at the following intervals: Screening; Pre-infusion (defined as 48 hours prior to start of first infusion); each infusion day; 48 hours after the last infusion; 7 days after the last infusion; 4 weeks after the last infusion. Assessments also occurred 24 hours post-delivery in subjects who delivered. Treatment with VEKLURY was stopped in subjects who were discharged from the hospital prior to the completion of 10 days of treatment.
Of the 25 pregnant subjects, median age was 33 years (Q1, Q3: 27 years, 37 years); 40% were White, 24% were Black, and 48% were Hispanic or Latino. A total of 9 subjects (36%) were on high-flow oxygen; 12 subjects (48%) were on low-flow oxygen; and 1 subject (4%) was on room air, at baseline. Three subjects (12%) did not have data available on baseline oxygen status. The overall median (Q1, Q3) duration of symptoms prior to hospitalization was 7 (6, 9) days. The overall median (Q1, Q3) duration of symptoms prior to first dose of VEKLURY was 8 (6, 9) days.
Of the 25 pregnant subjects, median gestational age was 28 weeks at baseline (range 22 to 33 weeks) and about half of subjects were in each of the second and third trimester of pregnancy. No clinically relevant differences in the pharmacokinetics of remdesivir or its metabolites (GS-704277 and GS-441524) were observed between pregnant (n=21) and non-pregnant (n=22) individuals [see Clinical Pharmacology (12.3)]. No difference in pharmacokinetics of remdesivir or its metabolites is expected between the first and second/third trimesters. The adverse reactions observed were consistent with those observed in clinical trials of VEKLURY in adults [see Adverse Reactions (6.1)]. There were no adverse reactions in infants born during the study (n=16).
Animal Data
Remdesivir was administered via intravenous injection to pregnant rats and rabbits (up to 20 mg/kg/day) on Gestation Days 6 through 17, and 7 through 20, respectively, and also to rats from Gestation Day 6 to Lactation/Post-partum Day 20. No adverse effects on embryo-fetal (rats and rabbits) or pre/postnatal (rats) development were observed in rats and rabbits at nontoxic doses in pregnant animals. During organogenesis, exposures to the predominant circulating metabolite (GS-441524) were 4 times higher (rats and rabbits) than the exposure in humans at the RHD. In a pre/postnatal development study, exposures to the predominant circulating metabolite of remdesivir (GS-441524) were similar to the human exposures at the RHD.
Risk Summary
A published case report describes the presence of remdesivir and active metabolite GS-441524 in human milk. Available data (n=11) from pharmacovigilance reports do not indicate adverse effects on breastfed infants from exposure to remdesivir and its metabolite through breastmilk. There are no available data on the effects of remdesivir on milk production. In animal studies, remdesivir and metabolites have been detected in the nursing pups of mothers given remdesivir, likely due to the presence of remdesivir in milk (see Data). The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for VEKLURY and any potential adverse effects on the breastfed child from VEKLURY or from the underlying maternal condition. Breastfeeding individuals with COVID-19 should follow practices according to clinical guidelines to avoid exposing the infant to COVID-19.
Data
Remdesivir and its metabolites were detected in the plasma of nursing rat pups, likely due to the presence of remdesivir and/or its metabolites in milk, following daily intravenous administration of remdesivir to pregnant rats from Gestation Day 6 to Lactation Day 20. Exposures in nursing pups were approximately 1% that of maternal exposure on Lactation Day 10. The concentration of remdesivir in animal milk does not necessarily predict the concentration of drug in human milk.
Exposure-Response
Remdesivir and metabolites exposure-response relationships and the time course of pharmacodynamics response are unknown.
Cardiac Electrophysiology
At 3 times the maximum recommended dose, clinically significant QTc interval prolongation was not observed.
Specific Populations
Pharmacokinetic differences based on sex, race, age, and renal function on the exposures of remdesivir were evaluated using population pharmacokinetic analysis. Sex and race did not affect the pharmacokinetics of remdesivir and its metabolites (GS-441524 and GS-704277).
Pregnant Individuals
The pharmacokinetics of remdesivir and its circulating metabolites (GS-441524 and GS-704277) were evaluated in pregnant individuals with COVID-19. Exposures (AUCtau, Cmax, and Ctau) of remdesivir and its circulating metabolites during pregnancy were similar to those in non-pregnant individuals (see Table 14).
Table 14 Multiple Dose PK ParametersStudy CO-US-590-5961 (IMPAACT).
of Remdesivir and Metabolites (GS-441524 and GS-704277) Following Intravenous Administration of VEKLURY to Pregnant and Non-Pregnant Individuals with COVID-19 Parameter MeanGeometric mean estimates. (90% CI) | Pregnant Individuals (N=21) | Non-Pregnant Individuals (N=22) |
|---|
| CI=Confidence Interval |
| Remdesivir | | |
| Cmax (nanogram per mL) | 1360 (978, 1890) | 1240 (891, 1720) |
| AUCtau (nanogram∙h per mL) | 1250 (916, 1700) N=18 | 1300 (1070, 1590) N=17 |
| GS-441524 | | |
| Cmax (nanogram per mL) | 113 (102, 126) | 121 (108, 136) |
| AUCtau (nanogram∙h per mL) | 1840 (1630, 2070) N=20 | 2050 (1780, 2350) N=21 |
| Ctau (nanogram per mL) | 51.6 (44.7, 59.6) | 57.1 (48.7, 66.9) |
| GS-704277 | | |
| Cmax (nanogram per mL) | 217 (187, 252) | 213 (188, 240) |
| AUCtau (nanogram∙h per mL) | 454 (406, 508) | 437 (384, 497) |
Patients with Renal Impairment
The pharmacokinetics of remdesivir and its metabolites (GS-441524 and GS-704277) and excipient SBECD were evaluated in healthy subjects, those with mild (eGFR 60–89 mL/minute/1.73m2), moderate (eGFR 30–59 mL/minute/1.73m2), severe (eGFR 15–29 mL/minute/1.73m2) renal impairment, or kidney failure (eGFR <15 mL/minute/1.73m2) on dialysis or not on dialysis following a single dose of up to 100 mg of VEKLURY (see Table 15); and in COVID-19 patients with severely reduced kidney function (AKI [defined as a 50% increase in serum creatinine within a 48-hour period that was sustained for ≥6 hours despite supportive care]; CKD [eGFR <30 mL/minute/1.73m2]; or ESRD [eGFR <15 mL/minute/1.73m2] requiring hemodialysis) receiving VEKLURY 200 mg loading dose on Day 1 followed by 100 mg from Day 2 to Day 5 (see Table 16). Pharmacokinetic exposures of remdesivir were not affected by renal function or timing of VEKLURY administration around dialysis.
Exposures of GS-441524, GS-704277, and SBECD were up to 7.9-fold, 2.8-fold, and 21-fold higher, respectively, in those with renal impairment compared to those with normal renal function (see Table 15 and Table 16). These changes are not considered to be clinically significant [see Adverse Reactions (6.1) and Use in Specific Populations (8.6)].
Remdesivir was not efficiently removed through hemodialysis. Average hemodialysis clearance of GS-441524 and GS-704277 was 149 mL/minute and 92.6 mL/minute, respectively.
Table 15 Comparison of PK ParametersExposures were estimated using noncompartmental analysis from a dedicated Phase 1 renal impairment Study GS-US-540-9015; single doses up to 100 mg were administered; each subject with renal impairment had a matched control participant enrolled with normal renal function (eGFR ≥90 mL/minute/1.73m2), same sex, and similar BMI (± 20%) and age (± 10 years).
of Remdesivir and Metabolites (GS-441524 and GS-704277) Following IV Administration of Single Dose VEKLURY to Adults with Renal ImpairmenteGFR was calculated using Modification of Diet in Renal Disease equation and values represent mL/minute/1.73m2.
as Compared to Adults with Normal Renal Function| Mean Ratio (90% CI) No effect=1.0 (0.5–2.0) | 60–89 mL per minute N=10 | 30–59 mL per minute N=10 | 15–29 mL per minute N=10 | <15 mL per minute |
|---|
Pre-hemodialysis N=6 | Post-hemodialysis N=6 | No dialysis N=3 |
|---|
| CI=Confidence Interval |
| Remdesivir | | | | | | |
| Cmax | 0.96 (0.71, 1.31) | 1.20 (1.01, 1.42) | 0.97 (0.83, 1.13) | 0.89 (0.67, 1.18) | 1.13 (0.79, 1.60) | 0.94 (0.65, 1.35) |
| AUCinf | 1.00 (0.75, 1.32) | 1.22 (0.98, 1.52) | 0.94 (0.83, 1.07) | 0.80 (0.59, 1.08) | 1.08 (0.72, 1.63) | 0.89 (0.55, 1.43) |
| GS-441524 | | | | | | |
| Cmax | 1.07 (0.90, 1.26) | 1.44 (1.13, 1.85) | 1.68 (1.28, 2.20) | 2.27 (1.72, 2.99) | 3.07 (2.21, 4.26) | 3.00 (2.63, 3.42) |
| AUCinf | 1.19 (0.97, 1.47) | 2.02 (1.57, 2.62) | 3.26 (2.39, 4.46) | 4.97 (3.65, 6.77) | 6.22 (4.44, 8.71) | 7.87 (6.49, 9.53) |
| GS-704277 | | | | | | |
| Cmax | 2.25 (1.20, 4.20) | 1.83 (1.34, 2.49) | 1.27 (0.96, 1.68) | 1.43 (1.00, 2.05) | 1.23 (0.84, 1.80) | 1.76 (1.19, 2.61) |
| AUCinf | 1.39 (1.13, 1.71) | 2.01 (1.48, 2.73) | 1.78 (1.27, 2.49) | 2.18 (1.61, 2.95) | 2.06 (1.42, 2.97) | 2.81 (1.79, 4.43) |
Table 16 Comparison of PK Parameters of Remdesivir and Metabolites (GS-441524 and GS-704277) Following IV Administration of VEKLURY (200 mg on Day 1 Followed by 100 mg Daily on Days 2–5) in Adults with COVID-19 withPopulation PK estimates for 30-minute IV infusion of remdesivir for 5 days (Study GS-US-540-5912, n=90).
or withoutPopulation PK estimates for 30-minute IV infusion of remdesivir for 3 days (Study GS-US-540-9012, n=148).
Severely Reduced Kidney FunctionAKI (defined as a 50% increase in serum creatinine within a 48-hour period that was sustained for ≥6 hours despite supportive care); CKD (eGFR <30 mL/minute/1.73m2); or ESRD (eGFR <15 mL/minute/1.73m2) requiring hemodialysis.
| Mean Ratio (90% CI) No effect=1.0 (0.5–2.0) | Remdesivir | GS-441524 | GS-704277 |
|---|
| CI=Confidence Interval; ND=Not detectable (at 24 hours post-dose) |
| Cmax | 1.39 (1.25, 1.54) | 4.98 (4.61, 5.38) | 1.84 (1.63, 2.08) |
| AUCtau | 1.79 (1.59, 2.01) | 6.59 (6.05, 7.18) | 3.94 (3.50, 4.43) |
| Ctau | ND | 5.82 (5.25, 6.45) | ND |
Patients with Hepatic Impairment
The pharmacokinetics of remdesivir and GS-441524 were evaluated in healthy subjects and those with moderate or severe hepatic impairment (Child-Pugh Class B or C) following a single dose of 100 mg of VEKLURY (see Table 17). Relative to subjects with normal hepatic function, mean exposures (AUCinf, Cmax) of remdesivir and GS-441524 were similar in subjects with moderate hepatic impairment and higher in subjects with severe hepatic impairment. The exposure differences in subjects with severe hepatic impairment are not considered to be clinically significant [see Use in Specific Populations (8.7)].
Table 17 Comparison of PK Parameters of Remdesivir and GS-441524 Following IV Administration of Single Dose VEKLURY to Adults with Hepatic Impairment as Compared to Adults with Normal Hepatic Function| Mean Ratio (90% CI) No effect=1.0 (0.5–2.0) | Moderate Hepatic Impairment N=10 | Severe Hepatic Impairment N=6 |
|---|
| CI=Confidence Interval |
| Remdesivir | | |
| AUCinf | 1.21 (0.87, 1.67) | 1.56 (1.20, 2.03) |
| Cmax | 1.10 (0.75, 1.60) | 1.03 (0.70, 1.51) |
| Unbound AUCinf | 1.15 (0.86, 1.54) | 2.44 (1.93, 3.08) |
| Unbound Cmax | 1.04 (0.73, 1.48) | 1.57 (1.08, 2.29) |
| GS-441524 | | |
| AUCinf | 0.90 (0.69, 1.17) | 1.31 (0.93, 1.84) |
| Cmax | 1.09 (0.86, 1.38) | 1.48 (1.17, 1.86) |
| C24 | 0.93 (0.69, 1.24) | 1.16 (0.76, 1.77) |
Pediatric Patients
Population pharmacokinetic models for remdesivir and its circulating metabolites (GS-441524 and GS-704277), developed using pooled data from studies in healthy subjects and in adult and pediatric patients with COVID-19, were used to estimate pharmacokinetic exposures in pediatric patients aged from birth to <18 years and weighing ≥1.5 kg (Study 5823). Geometric mean estimated exposures (AUCtau, Cmax, and Ctau) for patients ≥28 days to <18 years old and weighing ≥3 kg (Cohorts 1–4 and 8, n=50) at the doses administered were 33% to 130% higher for remdesivir, 3% lower to 60% higher for GS-441524, and 32% to 124% higher for GS-704277 as compared to those in adult patients with COVID-19; however, the increases were not considered clinically significant. Individual estimated exposures (AUCtau, Cmax, and Ctau) for patients 14 to <28 days old, GA >37 weeks, and weighing ≥2.5 kg (Cohort 5, n=3); patients <14 days old, GA >37 weeks, and weighing ≥2.5 kg at birth (Cohort 6, n=1); and patients <56 days old, GA ≤37 weeks, and weighing ≥1.5 kg at birth (Cohort 7, n=1) at the doses administered were higher for remdesivir, GS-441524, and GS-704277 as compared to median exposures in adult patients with COVID-19; however, the increases were not considered clinically significant. As limited PK data were available in Cohorts 5–7, additional analyses were conducted using a simulated population.
Using age and weight distributions from pediatric growth charts, simulated population datasets were created for Cohorts 5–6. Modeling and simulation incorporating maturation functions that account for renal function and drug metabolizing enzyme ontogeny with age were used to predict exposures for subjects <28 days old, GA >37 weeks, and weighing ≥1.5 kg and subjects ≥28 days old and weighing ≥1.5 to <3 kg. Predicted geometric mean exposures (AUCtau, Cmax, and Ctau) at the recommended doses were 10% to 96% higher for remdesivir, 15% lower to 3% higher for GS-441524, and 14% lower to 132% higher for GS-704277 as compared to those in adult patients with COVID-19; however, changes in exposure were not considered clinically significant. Results of simulated population led to the recommended dosing regimen as they more closely align with adult exposures compared to the doses studied.
Plasma exposures of excipient SBECD were generally similar for all pediatric patients at the doses administered in Study GS-US-540-5823 and were similar compared to adults with normal renal function, although data are very limited [see Use in Specific Populations (8.4)].
The multiple dose PK parameters of remdesivir and metabolites in pediatric patients with COVID-19 in Cohorts 1–4 and 8 are provided in Table 18.
Table 18 Multiple Dose PK ParametersPopulation PK estimates for 30-minutes IV infusion of remdesivir for up to 10 days (Study GS-US-540-5823).
of Remdesivir and Metabolites (GS-441524 and GS-704277) Following Intravenous Administration of VEKLURY 100 mg (Cohorts 1 and 8) or 2.5 mg/kg (Cohorts 2–4) to Pediatric Patients with COVID-19 | Cohort 1 | Cohort 8 | Cohort 2 | Cohort 3 | Cohort 4 |
|---|
Parameter MeanGeometric mean estimates. (95% CI) | 12 to <18 Years and Weighing ≥40 kg (N=12) | <12 Years and Weighing ≥40 kg (N=5) | 28 Days to <18 Years and Weighing 20 to <40 kg (N=12) | 28 Days to <18 Years and Weighing 12 to <20 kg (N=11) | 28 Days to <18 Years and Weighing 3 to <12 kg (N=10) |
|---|
| CI=Confidence Interval |
| Remdesivir | | | | | |
| Cmax (nanogram per mL) | 3890 (3110, 4870) | 3920 (2260, 6820) | 5730 (4660, 7050) | 5570 (4250, 7300) | 4870 (3750, 6340) |
| AUCtau (nanogram∙h per mL) | 2470 (1920, 3160) | 2270 (1200, 4310) | 3510 (2560, 4820) | 3930 (2140, 7210) | 2910 (1880, 4510) |
| GS-441524 | | | | | |
| Cmax (nanogram per mL) | 196 (122, 315) | 163 (57.6, 461) | 183 (129, 260) | 171 (130, 223) | 205 (174, 241) |
| AUCtau (nanogram∙h per mL) | 3430 (1980, 5920) | 2640 (767, 9100) | 2370 (1500, 3740) | 2410 (1740, 3340) | 2850 (2290, 3540) |
| Ctau (nanogram per mL) | 98.5 (59.1, 164) | 76.2 (23.9, 243) | 59.9 (34.2, 105) | 68.9 (47.4, 100) | 79.7 (59.5, 107) |
| GS-704277 | | | | | |
| Cmax (nanogram per mL) | 308 (211, 450) | 266 (137, 514) | 419 (306, 575) | 444 (335, 587) | 385 (294, 504) |
| AUCtau (nanogram∙h per mL) | 819 (474, 1420) | 518 (192, 1400) | 753 (542, 1050) | 733 (504, 1060) | 687 (484, 973) |
Drug Interaction Studies
In vitro, remdesivir is a substrate for enzymes CYP3A, carboxylesterase 1 (CES1), and cathepsin A (CatA) and OATP1B1 and P-gp transporters; GS-704277 is a substrate for OATP1B1 and OATP1B3. In vitro, remdesivir is an inhibitor of CYP3A, UGT1A1, OATP1B1, OATP1B3, and MATE1; however, no clinically significant effects on substrates of UGT1A1 or MATE1 are expected. No inhibitory interactions were identified for GS-704277 or GS-441524 in vitro.
Remdesivir is not a substrate for CYP1A1, 1A2, 2B6, 2C9, 2C19, or OATP1B3. GS-704277 and GS-441524 are not substrates for CYP1A1, 1A2, 2B6, 2C8, 2C9, 2D6, or 3A5. GS-441524 is also not a substrate for CYP2C19 or 3A4. GS-704277 and GS-441524 are not substrates for OAT1, OAT3, OCT1, OCT2, MATE1, or MATE2k. GS-441524 is also not a substrate for OATP1B1 or OATP1B3.
Drug-drug interaction studies were conducted with VEKLURY. Table 19 summarizes the pharmacokinetic effects of other drugs on remdesivir and metabolites GS-704277 and GS-441524. Table 20 summarizes the effects of remdesivir on the pharmacokinetics of other drugs.
Table 19 Effect of Other Drugs on Remdesivir and Metabolites GS-704277 and GS-441524| Coadministered Drug | Dose of Coadministered Drug (mg) | Remdesivir Dose (mg) | N | Mean Ratio (90% CI) of Remdesivir, GS-704277, and GS-441524 PK With/Without Coadministered Drug No Effect = 1.00 (0.70–1.43) |
|---|
| Cmax | AUCinf | C24 |
|---|
| CI=confidence interval |
| Cyclosporin A | 400 single dose | 100 single dose | 9 | remdesivir | 1.49 (1.38–1.60) | 1.89 (1.77–2.02) | - |
| GS-704277 | 2.51 (2.26–2.78) | 2.97 (2.75–3.20) | - |
| GS-441524 | 1.17 (1.12–1.22) | 1.03 (0.99–1.08) | 1.02 (0.95–1.10) |
| Carbamazepine | 300 twice daily | 100 single dose | 8 | remdesivir | 0.87 (0.78–0.97) | 0.92 (0.83–1.02) | - |
| GS-704277 | 0.96 (0.84–1.10) | 0.98 (0.92–1.05) | - |
| GS-441524 | 0.97 (0.88–1.07) | 0.83 (0.78–0.89) | 0.71 (0.64–0.78) |
Table 20 Effect of Remdesivir on the Pharmacokinetics of Other Drugs| Coadministered Drug | Dose of Coadministered Drug (mg) | Remdesivir Dose (mg) | N | Mean Ratio (90% CI) of Coadministered Drug PK With/Without Remdesivir No Effect = 1.00 (0.80–1.25) |
|---|
| Cmax | AUCinf |
|---|
| CI=confidence Interval |
| Midazolam Interaction study conducted in healthy volunteers. | 2.5 single dose | 200 single dose | 19 | 1.29 (1.19–1.41) | 1.20 (1.14–1.26) |
| Midazolam | 2.5 single dose | 200 single dose followed by 100 once daily (10 doses) Midazolam administered with last dose of remdesivir. | 14 | 1.45 (1.23– 1.70) | 1.30 (1.16– 1.45) |
| Pitavastatin | 2 single dose | 200 single dose | 20 | 1.05 (0.92–1.20) | 1.17 (1.09–1.24) |
Mechanism of Action
Remdesivir is an inhibitor of the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp), which is essential for viral replication. Remdesivir is an adenosine nucleotide prodrug that distributes into cells where it is metabolized to a nucleoside monophosphate intermediate by carboxyesterase 1 and/or cathepsin A, depending upon the cell type. The nucleoside monophosphate is subsequently phosphorylated by cellular kinases to form the pharmacologically active nucleoside triphosphate metabolite (GS-443902). Remdesivir triphosphate (RDV-TP) acts as an analog of adenosine triphosphate (ATP) and competes with high selectivity (3.65-fold) over the natural ATP substrate for incorporation into nascent RNA chains by the SARS-CoV-2 RdRp, which results in delayed chain termination (position i+3) during replication of the viral RNA. In a biochemical assay assessing RDV-TP incorporation by the MERS-CoV RdRp complex, RDV-TP inhibited RNA synthesis with an IC50 value of 0.032 µM. RDV-TP can also inhibit viral RNA synthesis following its incorporation into the template viral RNA as a result of read-through by the viral polymerase that may occur at higher nucleotide concentrations. When remdesivir nucleotide is present in the viral RNA template, the efficiency of incorporation of the complementary natural nucleotide is compromised, thereby inhibiting viral RNA synthesis. Remdesivir triphosphate is a weak inhibitor of mammalian DNA and RNA polymerases, including human mitochondrial RNA polymerase.
Antiviral Activity
In Cell Culture
Remdesivir exhibited cell culture antiviral activity against a clinical isolate of SARS‑CoV‑2 in primary human airway epithelial (HAE) cells with a 50% effective concentration (EC50) of 9.9 nM after 48 hours of treatment. Remdesivir inhibited the replication of SARS-CoV-2 in the continuous human lung epithelial cell lines Calu-3 and A549-hACE2 with EC50 values of 280 nM after 72 hours of treatment and 115 nM after 48 hours of treatment, respectively.
Remdesivir EC50 values for SARS-CoV-2 in A549-hACE2 cells were not different when combined with chloroquine phosphate or hydroxychloroquine sulfate at concentrations up to 2.5 µM. In a separate study, the antiviral activity of remdesivir was antagonized by chloroquine phosphate in a dose-dependent manner when the two drugs were co-incubated at clinically relevant concentrations in HEp-2 cells infected with respiratory syncytial virus (RSV). Higher remdesivir EC50 values were observed with increasing concentrations of chloroquine phosphate. Increasing concentrations of chloroquine phosphate or hydroxychloroquine sulfate reduced formation of remdesivir triphosphate in A549-hACE2, HEp-2, and normal human bronchial epithelial cells.
Based on cell culture susceptibility testing by virus yield reduction assay and/or N protein ELISA assay, remdesivir retained similar antiviral activity against clinical isolates of SARS-CoV-2 variants compared to an earlier lineage SARS-CoV-2 (lineage A) isolate, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), Epsilon (B.1.429), Zeta (P.2), Iota (B.1.526), Kappa (B.1.617.1), Lambda (C.37), and Omicron variants (including B.1.1.529/BA.1, BA.2, BA.2.12.1, BA.2.75, BA.2.86, BA.4, BA.4.6, BA.5, BF.5, BF.7, BQ.1, BQ.1.1, CH.1.1, EG.1.2, EG.5.1, EG.5.1.4, FL.22, HK.3, HV.1, JN.1, XBB, XBB.1.5, XBB.1.5.72, XBB.1.16, XBB.2.3.2, XBC.1.6, and XBF). For these variants, the EC50 fold change values ranged between 0.2 and 2.3 compared to an earlier lineage SARS-CoV-2 (lineage A) isolate. Using the SARS-CoV-2 replicon system, remdesivir retained similar antiviral activity against Omicron subvariants JN.1.7, JN.1.18, KP.2, KP.3, LB.1, and XBB.1.9.2 compared to the wildtype reference replicon (lineage B).
In Clinical Trials
SARS-CoV-2 RNA shedding results from GS-US-540-5776 (ACTT-1) indicate that remdesivir does not significantly reduce the amount of detectable SARS-CoV-2 RNA in oropharyngeal or nasopharyngeal swabs or plasma samples in hospitalized patients compared to placebo, and SARS-CoV-2 RNA shedding results from GS-US-540-9012 indicate that remdesivir does not significantly reduce the amount of detectable SARS-CoV-2 RNA in nasopharyngeal swabs in non-hospitalized patients compared to placebo.
Resistance
In Cell Culture
SARS-CoV-2 isolates with reduced susceptibility to remdesivir have been selected in cell culture. In a selection with GS-441524, the parent nucleoside of remdesivir, virus pools emerged expressing amino acid substitutions at V166A, N198S, S759A, V792I, C799F, and C799R in the viral RdRp (nsp12). When these substitutions were individually introduced into a wild-type recombinant virus by site-directed mutagenesis, 1.7- to 3.5-fold reductions in susceptibility to remdesivir were observed. In a cell culture resistance selection experiment with remdesivir, nsp12 substitution E802D emerged, resulting in a 1.4- to 2.5-fold reduction in susceptibility to remdesivir. In another selection with remdesivir using a SARS-CoV-2 isolate containing the P323L substitution in the viral polymerase, a single amino acid substitution at V166L emerged. Recombinant SARS-CoV-2 with substitutions at P323L alone or P323L+V166L in combination exhibited 1.3- and 1.5-fold reductions in remdesivir susceptibility, respectively.
Cell culture resistance profiling of remdesivir using the rodent CoV murine hepatitis virus identified two substitutions (F476L and V553L) in the viral RdRp (nsp12) at residues conserved across CoVs. Introduction of the corresponding substitutions (F480L and V557L) into SARS-CoV resulted in 6-fold reduction in susceptibility to remdesivir in cell culture and attenuated SARS-CoV pathogenesis in a mouse model. When individually introduced into a SARS-CoV-2 recombinant virus, the corresponding substitutions at F480L and V557L each conferred 2-fold reduced susceptibility to remdesivir.
In Clinical Studies
In a literature publication, the SARS-CoV-2 nsp12 E802D substitution previously identified in a resistance selection experiment emerged in one individual treated with remdesivir. The E802D substitution resulted in a 1.4- to 2.5-fold increase in the remdesivir EC50 value. In other literature publications, the nsp12 substitutions E136A, V166L+I536V, and C464Y were observed in three immunocompromised individuals treated with remdesivir, with one substitution observed per individual. The E136A, V166L+I536V, and C464Y substitutions resulted in 4.0-, 3.2-, and 2.8-fold reduced susceptibility to remdesivir in a subgenomic replicon assay.
In Study CO-US-540-5776 (ACTT-1), among 61 subjects with baseline and post-baseline sequencing data available, the rate of emerging substitutions in the viral RdRp (nsp12) was similar in subjects treated with VEKLURY compared to placebo. Two subjects treated with VEKLURY had an emergent substitution previously identified in resistance selection experiments (nsp12 V792I in one and C799F in the other). These substitutions are associated with 2.2- and 2.5-fold decreases in remdesivir susceptibility, respectively, based on assessments of clinical isolates. In one subject treated with VEKLURY, nsp12 V792F emerged at low frequency and was associated with a 1.8-fold decrease in remdesivir susceptibility.
In Study GS-US-540-5773, among 19 subjects treated with VEKLURY with baseline and post-baseline sequencing data available, the V792F substitution in viral RdRp (nsp12) emerged at low frequency in one subject.
In Study GS-US-540-9012, among 244 subjects with baseline and post-baseline sequencing data available, the rate of emerging substitutions in the viral RdRp (nsp12) was similar in subjects treated with VEKLURY compared to placebo. In one subject treated with VEKLURY, one substitution in the RdRp (nsp12 A376V) emerged and was associated with a 12.6-fold decrease in remdesivir susceptibility in a subgenomic replicon assay. This subject was not hospitalized and showed alleviation of all baseline symptoms, except loss of taste and smell, prior to or on Day 14.
In Study GS-US-540-5912, among 60 subjects with baseline and post-baseline sequencing data available, substitutions in the viral RdRp (nsp12) emerged in 8 subjects treated with VEKLURY. In 4 subjects treated with VEKLURY, three substitutions in the RdRp (nsp12 E136V, M794I, or C799F) emerged and were associated with 2.9-, 2.9-, and 3.4-fold reduced susceptibility to remdesivir in a subgenomic replicon assay.
In Study GS-US-540-5823, among pediatric subjects with baseline and post-baseline sequencing data available, treatment-emergent substitutions in the viral RdRp (nsp12) were observed in 3 of 27 subjects treated with VEKLURY and were evaluated for susceptibility to remdesivir. In one subject, two substitutions (nsp12 substitutions V166L and V792I) emerged and were associated with 1.85- and 3.6-fold decreases in remdesivir susceptibility relative to reference, respectively. This subject was hospitalized at baseline, recovered from COVID-19, and was released from the hospital on Day 13. None of the substitutions observed in any of the other genes (nsp9–10, nsp13–14) encoding for proteins of the viral replication-transcription complex have been associated with reduced susceptibility to remdesivir.
The relationship between the level of reduced susceptibility to remdesivir observed in subgenomic replicon assays and the inhibition of SARS-CoV-2 replication by remdesivir in humans has not been fully established.
Carcinogenesis and Mutagenesis
Given the short-term administration of VEKLURY for the treatment of COVID-19, long-term animal studies to evaluate the carcinogenic potential of remdesivir were not conducted.
Remdesivir was not genotoxic in a battery of assays, including bacterial mutagenicity, chromosome aberration using human peripheral blood lymphocytes, and in vivo rat micronucleus assays.
Impairment of Fertility
Nonclinical toxicity studies in rats demonstrated no adverse effect on male fertility at exposures of the predominant circulating metabolite (GS-441524) approximately 2 times the exposure in humans at the RHD.
Reproductive toxicity, including decreases in corpora lutea, numbers of implantation sites, and viable embryos, was seen when remdesivir was administered by daily intravenous administration at a systemically toxic dose (10 mg/kg) in female rats 14 days prior to mating and during conception; exposures of the predominant circulating metabolite (GS-441524) were 1.3 times the exposure in humans at the RHD.
Infants, children, and adolescents: At baseline, median age was 7 years (Q1, Q3: 2 years, 12 years); 57% were female, 70% were White, 30% were Black, and 44% were Hispanic or Latino; median weight was 25 kg (range: 4 to 192 kg). Subjects in this trial were unvaccinated. A total of 12 subjects (23%) were on invasive mechanical ventilation, 18 (34%) were on non-invasive ventilation or high-flow oxygen; 10 (19%) were on low-flow oxygen; and 13 (25%) were on room air, at baseline. The overall median (Q1, Q3) duration of symptoms and hospitalization prior to first dose of VEKLURY was 5 (3, 7) days and 1 (1, 3) day, respectively.
The descriptive outcome analyses showed treatment with VEKLURY for up to 10 days resulted in an overall median (Q1, Q3) change from baseline in clinical status (assessed on a 7-point ordinal scale ranging from death [score of 1] to ventilatory support and decreasing levels of oxygen to hospital discharge [score of 7]) of +2.0 (1.0, 4.0) points on Day 10.
Recovery (defined as an improvement from a baseline clinical status score of 2 through 5 to a score of 6 or 7, or an improvement from a baseline score of 6 to a score of 7) was reported for 62% of subjects on Day 10; median (Q1, Q3) time to recovery was 7 (5, 16) days.
Overall, 60% of subjects were discharged by Day 10, and 83% of subjects were discharged by Day 30. Three subjects (6%) from Cohorts 1–4 and Cohort 8 died during the study.
Neonates and infants: At baseline, subjects ranged in age from 12 to 30 days; 3/5 were female, 4/5 were White, 1/5 was Black; weight ranged from 2.2 to 3.5 kg. Three subjects were on invasive mechanical ventilation and 2 were on high-flow oxygen. The duration of symptoms and hospitalization prior to first dose of VEKLURY ranged from 2 to 9 days and 1 to 9 days, respectively.
The descriptive outcome analyses showed treatment with VEKLURY for up to 10 days resulted in recovery (defined as an improvement from a baseline clinical status score of 2 through 5 to a score of 6 or 7, or an improvement from a baseline score of 6 to a score of 7) for 3 subjects, including for one subject by Day 10. Time to recovery ranged from 9 to 19 days.
Overall, a total of 3 subjects were discharged by Day 30, of which one subject was discharged by Day 10. No subjects from Cohorts 5–7 died during the study.
How Supplied
VEKLURY for injection, 100 mg (NDC 61958-2901-2) is supplied as a single-dose vial containing a sterile, preservative-free white to off-white to yellow lyophilized powder. It requires reconstitution and further dilution prior to administration by intravenous infusion [see Dosage and Administration (2.5)]. Discard unused portion. The container closure is not made with natural rubber latex.
Hypersensitivity Reactions
Inform patients that hypersensitivity reactions have been seen in patients receiving VEKLURY during and after infusion. Advise patients to inform their healthcare provider if they experience any of the following: changes in heart rate; fever; shortness of breath, wheezing; swelling of the lips, face, or throat; rash; nausea; sweating; or shivering [see Warnings and Precautions (5.1)].
Increased Risk of Transaminase Elevations
Inform patients that VEKLURY may increase the risk of hepatic laboratory abnormalities. Advise patients to alert their healthcare provider immediately if they experience any symptoms of liver inflammation [see Warnings and Precaution (5.2)].
Drug Interactions
Inform patients that VEKLURY may interact with other drugs. Advise patients to report to their healthcare provider the use of any other prescription or nonprescription medication or herbal products, including chloroquine phosphate or hydroxychloroquine sulfate [see Warnings and Precautions (5.3), Drug Interactions (7), and Microbiology (12.4)].
Pregnancy
Inform patients to notify their healthcare provider in the event of a pregnancy [see Use in Specific Populations (8.1)].
VEKLURY is a trademark of Gilead Sciences, Inc., or its related companies. All other trademarks referenced herein are the property of their respective owners.
© 2026 Gilead Sciences, Inc. All rights reserved